Advertisement

Current Fungal Infection Reports

, Volume 7, Issue 3, pp 244–251 | Cite as

Lateral-Flow Device for Diagnosis of Fungal Infection

  • Christopher R. Thornton
Advances in Diagnosis of Invasive Fungal Infections (U Binder, Section Editor)

Abstract

Invasive aspergillosis (IA) is a life-threatening complication of haematological malignancy and haematopoietic stem cell transplantation caused by the ubiquitous fungus Aspergillus. Current diagnosis of IA is multifaceted relying on data from clinical, radiological, and microbiological sources. The detection of Aspergillus biomarkers provides strategies both to pre-empt and to exclude disease, but the choice of biomarker assays is limited, requiring specialist equipment and training. This review examines recent advances in the accurate diagnosis of IA through the development of an Aspergillus lateral-flow device (LFD) incorporating a monoclonal antibody, JF5, which detects an antigenic marker of active infection. Recent trials using bronchoalveolar lavage fluids and serum samples from humans and from animal models of disease, have demonstrated the utility of the LFD as a rapid and user-friendly adjunct test for the quick and accurate diagnosis of pulmonary infections.

Keywords

Aspergillus Aspergillosis Candida Cryptococcus β-glucan Galactomannan Hybridoma technology Monoclonal antibody Lateral-flow device 

Notes

Disclaimer

The comments and conclusions in this report are the thoughts and observations of the author.

Conflict of Interest

The author developed the Aspergillus monoclonal antibody JF5 and the Aspergillus LFD described in this article, and is the CEO, Technical Director, and a shareholder of the University of Exeter spin-out company ISCA Diagnostics Limited, which has been granted patents, and may receive royalties for the products listed above.

References

Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance

  1. 1.
    Thompson GR, Patterson TF. Pulmonary aspergillosis. Semin Respir Crit Care Med. 2008;29:103–10.PubMedCrossRefGoogle Scholar
  2. 2.
    Miceli MH, Díaz JA, Lee SA. Emerging opportunistic yeast infections. Lancet Infect Dis. 2011;11:142–51.PubMedCrossRefGoogle Scholar
  3. 3.
    Walsh TJ, Groll AH, Hiemenz J. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect. 2004;10:48–66.PubMedCrossRefGoogle Scholar
  4. 4.
    • Dagenais TRT, Keller NP. Pathogenesis of Aspergillus fumigatus in invasive aspergillosis. Clin Microbiol Rev. 2009;22(3):447–65. A contemporary review of the biology of A. fumigatus, airway colonization, adaptation to the mammanlian lung environment and its interaction with cells of the immune system.PubMedCrossRefGoogle Scholar
  5. 5.
    Ainsworth GC: Aspergillosis. In Introduction to the history of medical and verterinary mycology. Cambridge University Press; 2002:47–9.Google Scholar
  6. 6.
    Thornton CR. Development of an immunochromatographic lateral flow device for rapid serodiagnosis of invasive aspergillosis. Clin Vacc Immunol. 2008;15:1095–105.CrossRefGoogle Scholar
  7. 7.
    Beirão F, Araujo R. State of the art diagnostic of mould diseases: a practical guide for clinicians. Eur J Clin Microbiol Infect Dis. 2012. doi: 10.1007/s10096-012-1722–7.PubMedGoogle Scholar
  8. 8.
    Johnson GL, Bibby DF, Wong S, et al. A MIQE-Compliant Real-Time PCR Assay for Aspergillus Detection. PLoS One. 2012;7(7):e40022.PubMedCrossRefGoogle Scholar
  9. 9.
    Denning DW. Invasive aspergillosis. Clin Infect Dis. 1998;26:781–805.PubMedCrossRefGoogle Scholar
  10. 10.
    • Levitz SM. Innate recognition of fungal cell walls. PLoS Pathog. 2010;6(4):e1000758. This article reviews current knowledge of how the human host recognizes fungal pathogens through cell wall ligands and cognate phagocytic receptors.PubMedCrossRefGoogle Scholar
  11. 11.
    Bozza S, Gaziano R, Spreca A, et al. Dendritic cells transport conidia and hyphae of Aspergillus fumigatus from the airways to the draining lymph nodes and initiate disparate Th reponses to the fungus. J Immunol. 2002;168:1362–71.PubMedGoogle Scholar
  12. 12.
    • Barton R, (2013). Laboratory diagnosis of invasive aspergillosis: from diagnosis to prediction to outcome. Scientifica, Hindawi Publishing Corporation. Available at http://www.hindawi.com/journals/scientifica/2013/459405/Accessed January 2013. A comprehensive review of the laboratory diagnosis of invasive aspergillosis.
  13. 13.
    Thornton CR. Detection of Invasive Aspergillosis. Adv Appl Microbiol. 2008;7:187–216.Google Scholar
  14. 14.
    •• De Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European Organisation for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis. 2008;46:1813–21. This article defines the diagnostic criteria needed to establish possible, probable, or proven invasive fungal disease, and is a revised version of the 2002 consensus group guidelines.PubMedCrossRefGoogle Scholar
  15. 15.
    •• White PL, Parr C, Thornton C, et al. An evaluation of real-time PCR, galactomannan ELISA and a novel lateral-flow device for diagnosis of invasive aspergillosis. 2013;51:1510–16. A large-scale evaluation of LFD diagnosis of IA, using serum from haematological patients, and comparison of assay sensitivity and specificity as a stand-alone test or when used in combination with commercial GM-EIA and PCR assays.Google Scholar
  16. 16.
    • Thornton CR, Johnson G, Agrawal S. Detection of invasive pulmonary aspergillosis in haematological malignancy patients by using lateral-flow technology. J Vis Exp. 2012;61:e3721. An open-access video journal demonstrating the mechanics of the Aspergillus LFD, serum and BALf preparation, and interpretation of test results using human BALf samples.Google Scholar
  17. 17.
    Hsu JL, Ruoss SJ, Bower ND, et al. Diagnosing invasive fungal infections in critically ill patients. Crit Rev Microbiol. 2011;37(4):277–312.PubMedCrossRefGoogle Scholar
  18. 18.
    Obayashi T, Negishi K, Suzuki T, et al. Reappraisal of the serum (1→3)-β-D-glucan assay for the diagnosis of invasive fungal infections – a study based on autopsy cases from 6 years. Clin Infect Dis. 2008;46(12):1864–70.PubMedCrossRefGoogle Scholar
  19. 19.
    Verweij PE, Mennink-Kersten MASH. Issues with galactomannan testing. Med Mycol. 2006;44:179–83.CrossRefGoogle Scholar
  20. 20.
    Klont RR, Mennink-Kersten MA, Verweij PE. Utility of Aspergillus antigen detection in specimens other than serum specimens. Clin Infect Dis. 2004;15:1467–74.CrossRefGoogle Scholar
  21. 21.
    Park SY, Lee S-O, Choi S-H, et al. Aspergillus galactomannan antigen assay in bronchoalveolar lavage fluid for diagnosis of invasive pulmonary aspergillosis. J Infect. 2010;61:492–8.PubMedCrossRefGoogle Scholar
  22. 22.
    •• Hoenigl M, Koidl C, Duettman W, et al. Bronchoalveolar lavage lateral-flow device test for invasive pulmonary aspergillosis diagnosis in haematological malignancy and solid organ transplant patients. J Infect. 2012;65:588–91. LFD detection of IA using human BALf samples and its performance compared to the commercial Platelia GM-EIA.PubMedCrossRefGoogle Scholar
  23. 23.
    Buess M, Cathomas G, Halter J, et al. Aspergillus-PCR in brochoalveolar lavage for detection of invasive pulmonary aspergillosis in immunocompromised patients. BMC Infect Dis. 2012;12:237–44.PubMedCrossRefGoogle Scholar
  24. 24.
    McDonagh A, Federova ND, Crabtree J, et al. Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathogens. 2008;4(9):e1000154.PubMedCrossRefGoogle Scholar
  25. 25.
    Cairns T, Minuzzi F, Bignell E. The host-infecting fungal transcriptome. FEMS Microbiol Lett. 2010;307:1–11.PubMedCrossRefGoogle Scholar
  26. 26.
    Gardiner DM, Waring P, Howlett BJ. The epipolythiodioxopiperazine (ETP) class of fungal toxins: distribution, mode of action, functions and biosynthesis. Microbiology. 2005;151:1021–32.PubMedCrossRefGoogle Scholar
  27. 27.
    Spikes S, Xu R, Nguyen CK, et al. Gliotoxin production in Aspergillus fumigatus contributes to host-specific differences in virulence. J Infect Dis. 2008;197:479–86.PubMedCrossRefGoogle Scholar
  28. 28.
    Sutton P, Newcombe NR, Waring P, et al. In vivo immunosuppressive activity of gliotoxin, a metabolite produced by human pathogenic fungi. Infect Immun. 1994;62:1192–8.PubMedGoogle Scholar
  29. 29.
    Pardo J, Urban C, Galvez EM, et al. The mitochondrial protein Bak is pivotal for gliotoxin-induced apoptosis and a critical host factor of Aspergillus fumigatus virulence in mice. J Cell Biol. 2006;174:509–19.PubMedCrossRefGoogle Scholar
  30. 30.
    Sugui JA, Pardo J, Chang YC, et al. Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell. 2007;6:1562–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Domingo MP, Colmenarejo C, Martínez-Lostao L, et al. Bis(methyl)gliotoxin proves to be a more stable and reliable marker for invasive aspergillosis than gliotoxin and suitable for use in diagnosis. Diagn Microbiol Infect Dis. 2012;73:57–64.PubMedCrossRefGoogle Scholar
  32. 32.
    Eisendle M, Schrettl M, Kragl C, et al. The intracellular siderophore ferricrocin is involved in iron storage, oxidative-stress resistance, germination, and sexual development in Aspergillus nidulans. Eukaryot Cell. 2006;5:1596–603.PubMedCrossRefGoogle Scholar
  33. 33.
    Haas H, Schoeser M, Lesuisse E, et al. Characterisation of the Aspergillus nidulans transporters for the siderophores enterobactin and triacetylfusarinine C. Biochem J. 2003;371:505–13.PubMedCrossRefGoogle Scholar
  34. 34.
    Petrik M, Haas H, Dobrozemsky G, et al. 68Ga-Siderophores for PET imaging of invasive aspergillosis:proof of principle. J Nucl Med. 2010;51:639–45.PubMedCrossRefGoogle Scholar
  35. 35.
    Schrettl M, Kim HS, Eisendle M, et al. SreA-mediated iron regulation in Aspergillus fumigatus. Mol Microbiol. 2008;70:27–43.PubMedCrossRefGoogle Scholar
  36. 36.
    Zou M, Tang L, Zhao S, et al. Systematic review and meta-analysis of detecting galactomannan in bronchoalveolar lavage fluid for diagnosing invasive aspergillosis. PLoS One. 2012;7(8):e43347.PubMedCrossRefGoogle Scholar
  37. 37.
    Köhler G, Milstein C. Continuous culture of fused cells secreting antibody of predefined specificity. Nature. 1975;256:495–7.PubMedCrossRefGoogle Scholar
  38. 38.
    Hirschi S, Letscher-Bru V, Pottecher J, et al. Disseminated Trichosporon mycotoxinivorans, Aspergillus fumigatus and Scedosporium apiospermum coinfection after lung and liver transplantation in a cystic fibrosis patient. J Clin Microbiol. 2012;50:4168–70.PubMedCrossRefGoogle Scholar
  39. 39.
    Iweala OI. HIV diagnostic tests: an overview. Contraception. 2004;70:141–7.PubMedCrossRefGoogle Scholar
  40. 40.
    Shyu RH, Shyu HF, Liu HW, et al. Colloidal gold-based immunochromatographic assay for detection of ricin. Toxicon. 2002;40:255–8.PubMedCrossRefGoogle Scholar
  41. 41.
    Smits HL, Eapen CK, Sugathan S, et al. Lateral-flow assay for rapid serodiagnosis of human leptospirosis. Clin Diagn Lab Immunol. 2001;8:166–9.PubMedGoogle Scholar
  42. 42.
    Marot-Leblond A, Grimaud L, David S, et al. Evaluation of a rapid immunochromatographic assay for identification of Candida albicans and Candida dubliniensis. J Clin Microbiol. 2004;42(11):4956–60.PubMedCrossRefGoogle Scholar
  43. 43.
    Jarvis NJ, Percival A, Bauman S, et al. Evaluation of a novel point-of-care cryptococcal antigen test on serum, plasma, and urine from patients with HIV-associated cryptococcal meningitis. Clin Infect Dis. 2011;53:1019–23.PubMedCrossRefGoogle Scholar
  44. 44.
    Krajaejun T, Imkhieo S, Intaramat A, et al. Development of an immunochromatographic test for rapid serodiagnosis of human pythiosis. Clin Vacc Immunol. 2009;16:506–9.CrossRefGoogle Scholar
  45. 45.
    Marcilla A, Monteagudo C, Mormeneo S, et al. Monoclonal antibody 3H8: a useful tool in the diagnosis of candidiasis. Microbiology. 1999;145:695–701.PubMedCrossRefGoogle Scholar
  46. 46.
    Marot-Leblond A, Grimaud L, Nail S, et al. New monoclonal antibody specific for Candida albicans germ tube. J Clin Microbiol. 2000;38:61–7.PubMedGoogle Scholar
  47. 47.
    Brandt S, Thorkildson P, Kozel TR. Monoclonal antibodies reactive with immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcus neoformans. Clin Diagn Lab Immunol. 2003;10:903–9.PubMedGoogle Scholar
  48. 48.
    Percival A, Thorkildson P, Kozel TR. Monoclonal antibodies specific for immunorecessive epitopes of glucuronoxylomannan, the major capsular polysaccharide of Cryptococcocus neoformans, reduce serotype bias in immunoassay for cryptococcal antigen. Clin Vacc Immunol. 2011;18:1292–6.CrossRefGoogle Scholar
  49. 49.
    Wiederhold NP, Thornton CR, Najvar LK, et al. Comparison of lateral flow technology and galactomannan and (1→3)-β-D-glucan assays for detection of invasive pulmonary aspergillosis. Clin Vacc Immunol. 2009;16:1844–6.CrossRefGoogle Scholar
  50. 50.
    •• Wiederhold NP, Najvar LK, Bocanegra R, et al. Inter-Laboratory and Inter-Study Reproducibility of a Novel Lateral-Flow Device and the Influence of Antifungal Therapy on the Detection of Invasive Pulmonary Aspergillosis. J Clin Microbiol. 2013;51:459–65. A study using serum and BALf from an established animal model of IA, comparing the LFD, and commercial GM-EIA and β-glucan tests for disease diagnosis and the effect of antifungal treatments on assay sensitivities.PubMedCrossRefGoogle Scholar
  51. 51.
    McCulloch E, Ramage G, Rajendran R, et al. Antifungal treatment affects the laboratory diagnosis of invasive aspergillosis. J Clin Pathol. 2012;65:83–6.PubMedCrossRefGoogle Scholar
  52. 52.
    Buchheidt D. Therapy with antifungals decreases the diagnostic performance of PCR for diagnosing invasive aspergillosis in bronchoalveolar lavage samples of patients with haematological malignancies. J Antimicrob Chemother. 2012;67:2260–7.PubMedCrossRefGoogle Scholar
  53. 53.
    Vanselow M, Brandt ME, Park BJ. Diagnosis and management of Cryptococcal disease in resource-limited settings. Curr Fungal Infect Rep. 2012;Google Scholar
  54. 54.
    O’Farrell B. Evolution of lateral flow-based immunoassay systems. In: Wong R, Tse H, editors. In Lateral Flow Immunoassay. New York: Humana Press; 2009. p. 1–35.CrossRefGoogle Scholar
  55. 55.
    Marcos JY, Pincus DH. Fungal diagnostics: review of commercially available methods. In: O’Connor L, Glynn B, editors. Fungal Diagnostics: Methods and Protocols, Methods in Molecular Biology. 968th ed. New York: Springer Science and Business Media; 2013. p. 25–54.CrossRefGoogle Scholar
  56. 56.
    Thornton CR. Tracking the emerging human pathogen Pseudallescheria boydii by using highly specific monoclonal antibodies. Clin Vacc Immunol. 2009;16:756–64.CrossRefGoogle Scholar
  57. 57.
    Thornton CR, Wills O. Immunodetection of fungal and oomycete pathogens: established and emerging threats to human health, animal welfare and global food security. Crit Rev Microbiol. 2013, in press.Google Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Biosciences, College of Life and Environmental SciencesUniversity of ExeterExeterUK

Personalised recommendations